{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:34:32Z","timestamp":1778092472286,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1245\/s10434-025-19072-0","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T21:28:05Z","timestamp":1769462885000},"page":"3849-3860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Shifting Paradigm: Utilization and Outcomes with Neoadjuvant Chemotherapy for cT4 and cN2 Colon Cancers"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-8516","authenticated-orcid":false,"given":"Bennett W.","family":"Hartley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivi W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punam","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atif","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesenia","family":"Rojas-Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest R.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek J.","family":"Erstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"19072_CR1","unstructured":"American cancer society. Key statistics for colorectal cancer. American cancer society. Accessed 02-12-2025"},{"key":"19072_CR2","unstructured":"American cancer society. Survival rates for colorectal cancer. American cancer society. Accessed 05-07-2024"},{"issue":"2","key":"19072_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5114\/pg.2018.81072","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89\u2013103. https:\/\/doi.org\/10.5114\/pg.2018.81072.","journal-title":"Prz Gastroenterol."},{"key":"19072_CR4","unstructured":"National comprehensive cancer network. Colon cancer (Version 1.2024). National comprehensive cancer network."},{"issue":"8","key":"19072_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/jco.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton D, Seymour M, Magill L, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541\u201352. https:\/\/doi.org\/10.1200\/jco.22.00046.","journal-title":"J Clin Oncol."},{"issue":"4","key":"19072_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/SLA.0000000000003454","volume":"271","author":"M Karoui","year":"2020","unstructured":"Karoui M, Rullier A, Piessen G, et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg. 2020;271(4):637\u201345. https:\/\/doi.org\/10.1097\/SLA.0000000000003454.","journal-title":"Ann Surg."},{"issue":"12","key":"19072_CR7","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905.","journal-title":"JAMA Oncol."},{"issue":"10","key":"19072_CR8","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00384-021-03945-3","volume":"36","author":"R Gosavi","year":"2021","unstructured":"Gosavi R, Chia C, Michael M, Heriot AG, Warrier SK, Kong JC. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2021;36(10):2063\u201370. https:\/\/doi.org\/10.1007\/s00384-021-03945-3.","journal-title":"Int J Colorectal Dis."},{"issue":"10","key":"19072_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10151-020-02289-4","volume":"24","author":"J Arredondo","year":"2020","unstructured":"Arredondo J, Pastor E, Simo V, et al. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review. Tech Coloproctol. 2020;24(10):1001\u201315. https:\/\/doi.org\/10.1007\/s10151-020-02289-4.","journal-title":"Tech Coloproctol."},{"key":"19072_CR10","unstructured":"Ding P, Li Y. Phase III study of neoadjuvant FOLFOXIRI chemotherapy versus immediate surgery for high-risk resectable stage II and III colon cancers. ClinicalTrials.gov identifier: NCT05194878. Ding P, Li Y. Recruiting, Sun Yat-sen University."},{"key":"19072_CR11","unstructured":"Iqbal, A. Phase II open-label trial of neoadjuvant atezolizumab in combination with CAPEOX for resectable non-metastatic proficient mismatch repair (PMMR) colon cancer. Clinicaltrials.gov identifier: NCT05870800. Not yet recruiting, Baylor College of Medicine."},{"key":"19072_CR12","unstructured":"Pd1 Antibody sintilimab \u00b1 chemoradiotherapy for locally advanced rectal cancer. Clinicaltrials.gov identifier: NCT04304209. Active, not recruiting, Sun Yat-sen University."},{"key":"19072_CR13","unstructured":"Multicenter, single-arm, open-label phase II clinical study of tislelizumab combined with chemotherapy (CAPOX) in the perioperative treatment of MSI-H\/dMMR stage II or III colorectal cancer. Clinicaltrials.gov identifier: NCT05841134. Not yet recruiting, The First Affiliated Hospital of Zhengzhou University."},{"key":"19072_CR14","unstructured":"Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: a multicentre, open-label, parallel-group, phase II-III, randomised superiority study. Clinicaltrials.gov identifier: NCT02758951. Active, not recruiting, Koen Rovers."},{"key":"19072_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.humpath.2022.05.006","volume":"126","author":"R Newland","year":"2022","unstructured":"Newland R, Ng K-S, Chapuis P, Chan C, Dent O. The association between tumour sub-site and local nodal and\/or distant metastasis at the time of resection of colorectal cancer: a prospective study of 3,360 consecutive cases. Human Pathol. 2022;126:121\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2022.05.006.","journal-title":"Human Pathol."},{"issue":"7","key":"19072_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41588-019-0423-x","volume":"51","author":"Z Hu","year":"2019","unstructured":"Hu Z, Ding J, Ma Z, et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 2019;51(7):1113\u201322. https:\/\/doi.org\/10.1038\/s41588-019-0423-x.","journal-title":"Nat Genet."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-19072-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:25:54Z","timestamp":1776255954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-19072-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["19072"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-19072-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest to report for the design or execution of this study. No authors have any commercial or financial interest in the subject of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}